Season 9 · Episode 23
S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
OncLive® On Air · OncLive® On Air
September 4, 202314m 57s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.